JP2024532734A - 複素環式化合物及び使用方法 - Google Patents

複素環式化合物及び使用方法 Download PDF

Info

Publication number
JP2024532734A
JP2024532734A JP2024507879A JP2024507879A JP2024532734A JP 2024532734 A JP2024532734 A JP 2024532734A JP 2024507879 A JP2024507879 A JP 2024507879A JP 2024507879 A JP2024507879 A JP 2024507879A JP 2024532734 A JP2024532734 A JP 2024532734A
Authority
JP
Japan
Prior art keywords
fluoro
pyrrolidin
methoxy
pyrido
pyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024507879A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024532734A5 (cg-RX-API-DMAC7.html
Inventor
ヤマノ,マイケル・エム
リー,ユンシャオ
ナバラトネ,プリマリ
メディナ,ホセ
チェン,ニン
ペタス,リピング
ラヒモフ,レーネ
リー,シャオフェン
ステルワーゲン,ジョン
マンオーニ,フランチェスコ
リー,カーシュエ
ランマン,ブライアン・アラン
ブルツ,ライアン・ポール
ジャオ,ウェイ
ルイ,ホワン
イーション,ジョセフィン
Original Assignee
アムジエン・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アムジエン・インコーポレーテツド filed Critical アムジエン・インコーポレーテツド
Publication of JP2024532734A publication Critical patent/JP2024532734A/ja
Publication of JP2024532734A5 publication Critical patent/JP2024532734A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024507879A 2021-08-10 2022-08-10 複素環式化合物及び使用方法 Pending JP2024532734A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163231543P 2021-08-10 2021-08-10
US63/231,543 2021-08-10
US202163289579P 2021-12-14 2021-12-14
US63/289,579 2021-12-14
PCT/US2022/039971 WO2023018812A1 (en) 2021-08-10 2022-08-10 Heterocyclic compounds and methods of use

Publications (2)

Publication Number Publication Date
JP2024532734A true JP2024532734A (ja) 2024-09-10
JP2024532734A5 JP2024532734A5 (cg-RX-API-DMAC7.html) 2025-08-19

Family

ID=85201014

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024507879A Pending JP2024532734A (ja) 2021-08-10 2022-08-10 複素環式化合物及び使用方法

Country Status (7)

Country Link
EP (1) EP4384160A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024532734A (cg-RX-API-DMAC7.html)
AU (1) AU2022325771A1 (cg-RX-API-DMAC7.html)
CA (1) CA3228310A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024001893A (cg-RX-API-DMAC7.html)
TW (1) TW202330529A (cg-RX-API-DMAC7.html)
WO (1) WO2023018812A1 (cg-RX-API-DMAC7.html)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020020307A2 (pt) 2018-04-04 2021-01-12 Arvinas Operations, Inc. Moduladores de proteólise e métodos de uso associados
WO2021085653A1 (en) 2019-10-31 2021-05-06 Taiho Pharmaceutical Co., Ltd. 4-aminobut-2-enamide derivatives and salts thereof
EP4067343A4 (en) 2019-11-29 2024-01-03 Taiho Pharmaceutical Co., Ltd. NEW PHENOLIC COMPOUND OR SALT THEREOF
WO2021215544A1 (en) 2020-04-24 2021-10-28 Taiho Pharmaceutical Co., Ltd. Kras g12d protein inhibitors
US12702658B2 (en) 2020-04-24 2026-08-11 Taiho Pharmaceutical Co., Ltd. Anticancer combination therapy with N-(1-acryloyl-azetidin-3-yl)-2-((1H-indazol-3-yl)amino)methyl)-1H-imidazole-5-carboxamide inhibitor of KRAS-G12C
WO2022109487A1 (en) 2020-11-23 2022-05-27 Merck Sharp & Dohme Corp. Spirocyclic-substituted 6,7-dihydro-pyrano[2,3-d]pyrimidine inhibitors of kras g12c mutant
US20260200925A1 (en) * 2021-11-24 2026-07-16 Merck Sharp & Dohme Llc Small molecule inhibitors of kras mutated proteins
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
AU2023265688A1 (en) 2022-05-06 2024-10-17 PAQ Therapeutics Inc. Kras g12d proteolysis targeting chimeras
WO2023213269A1 (en) * 2022-05-06 2023-11-09 Zai Lab (Shanghai) Co., Ltd. Amide-substituted heterocyclic compounds as kras g12d modulators and uses thereof
CN119365467A (zh) 2022-05-19 2025-01-24 基因泰克公司 氮杂-四环氧氮杂䓬化合物及其用途
EP4536364A1 (en) 2022-06-10 2025-04-16 Revolution Medicines, Inc. Macrocyclic ras inhibitors
JP2025519743A (ja) * 2022-06-15 2025-06-26 ミラティ セラピューティクス, インコーポレイテッド 汎KRas阻害剤のプロドラッグ
WO2024002373A1 (zh) * 2022-07-01 2024-01-04 苏州泽璟生物制药股份有限公司 取代嘧啶并环类抑制剂及其制备方法和应用
WO2024008068A1 (en) * 2022-07-04 2024-01-11 Jacobio Pharmaceuticals Co., Ltd. K-ras mutant protein inhibitors
CN116969977B (zh) * 2022-07-13 2026-05-01 重庆华森英诺生物科技有限公司 Pan-kras抑制剂
TW202426451A (zh) * 2022-08-24 2024-07-01 大陸商泰勵生物科技(上海)有限公司 具有抗kras突變腫瘤活性的化合物
KR20250109197A (ko) 2022-11-21 2025-07-16 트리라인 바이오사이언시스, 인크. 스피로환식 디하이드로피라노피리미딘 KRas 억제제
PE20260006A1 (es) 2023-01-26 2026-01-06 Arvinas Operations Inc Protacs degradadores de kras basados en cereblon y usos relacionados con los mismos
CN121487738A (zh) 2023-03-30 2026-02-06 锐新医药公司 诱导ras gtp水解的组合物和其用途
CN121487951A (zh) 2023-04-07 2026-02-06 锐新医药公司 大环ras抑制剂
WO2024211712A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
EP4695261A1 (en) 2023-04-14 2026-02-18 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
AU2024251341A1 (en) 2023-04-14 2025-10-16 Revolution Medicines, Inc. Crystalline forms of a ras inhibitor
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
WO2025006967A1 (en) 2023-06-30 2025-01-02 Bristol-Myers Squibb Company Kras inhibitors
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
KR20260054710A (ko) 2023-08-17 2026-04-22 트리라인 바이오사이언시스, 인크. 스피로시클릭 디히드로피라노피리미딘 KRas 저해제
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2025064848A1 (en) 2023-09-21 2025-03-27 Treeline Biosciences, Inc. Spirocyclic dihydropyranopyridine kras inhibitors
KR20260087586A (ko) 2023-10-03 2026-06-11 피에이큐 테라퓨틱스 인코포레이티드 Kras 단백질분해 표적화 키메라
CN122374018A (zh) 2023-10-06 2026-07-10 美国安进公司 用于癌症治疗的组合疗法
KR20260110993A (ko) 2023-10-09 2026-07-14 인사이트 코포레이션 Kras g12d 억제제 및 egfr 억제제를 포함하는 암 치료용 조합
US20250114346A1 (en) 2023-10-09 2025-04-10 Incyte Corporation Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
KR20260096846A (ko) 2023-10-20 2026-06-24 머크 샤프 앤드 돔 엘엘씨 Kras 단백질의 소분자 억제제
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025194054A1 (en) * 2024-03-14 2025-09-18 Amgen Inc. Spirocyclic compounds as modulators of kras and uses thereof
TW202602882A (zh) * 2024-03-14 2026-01-16 美商安進公司 作為kras調節劑的大環化合物及其用途
WO2025228384A1 (en) * 2024-04-30 2025-11-06 Hutchmed Limited Antibody-drug conjugates and use thereof
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025245127A1 (en) 2024-05-21 2025-11-27 Treeline Biosciences, Inc. Spirocyclic dihydropyranopyrimidine kras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026090333A1 (en) 2024-10-23 2026-04-30 Incyte Corporation Combination using a kras g12d inhibitor and chemotherapy combinations as well as their use in the treatment of cancer
US20260137674A1 (en) 2024-10-23 2026-05-21 Incyte Corporation Combination therapy using a kras g12d inhibitor, and a nucleoside analog, and/or a microtubule inhibitor
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150174132A1 (en) * 2005-05-26 2015-06-25 Synta Pharmaceuticals Corporation Method for treating b cell regulated autoimmune disorders
JP2016510042A (ja) * 2013-03-04 2016-04-04 中国科学院上▲海▼▲藥▼物研究所 ピリドピリミジンまたはピリミドピリミジン系化合物、その製造方法、薬剤組成物及びその用途
JP2019031476A (ja) * 2017-05-22 2019-02-28 アムジエン・インコーポレーテツド Kras g12c阻害剤及びその使用方法
WO2020146613A1 (en) * 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Kras g12c inhibitors
WO2021041671A1 (en) * 2019-08-29 2021-03-04 Mirati Therapeutics, Inc. Kras g12d inhibitors
WO2021081212A1 (en) * 2019-10-24 2021-04-29 Amgen Inc. Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer
WO2022132200A1 (en) * 2020-12-15 2022-06-23 Mirati Therapeutics, Inc. Azaquinazoline pan-kras inhibitors
WO2022228568A1 (zh) * 2021-04-30 2022-11-03 劲方医药科技(上海)有限公司 吡啶或嘧啶并环类化合物,其制法与医药上的用途
WO2022248885A2 (en) * 2021-05-28 2022-12-01 Redx Pharma Plc. Compounds
WO2023274324A1 (zh) * 2021-06-30 2023-01-05 上海艾力斯医药科技股份有限公司 一种含氮杂环化合物、其制备方法、中间体及应用

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150174132A1 (en) * 2005-05-26 2015-06-25 Synta Pharmaceuticals Corporation Method for treating b cell regulated autoimmune disorders
JP2016510042A (ja) * 2013-03-04 2016-04-04 中国科学院上▲海▼▲藥▼物研究所 ピリドピリミジンまたはピリミドピリミジン系化合物、その製造方法、薬剤組成物及びその用途
JP2019031476A (ja) * 2017-05-22 2019-02-28 アムジエン・インコーポレーテツド Kras g12c阻害剤及びその使用方法
WO2020146613A1 (en) * 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Kras g12c inhibitors
WO2021041671A1 (en) * 2019-08-29 2021-03-04 Mirati Therapeutics, Inc. Kras g12d inhibitors
WO2021081212A1 (en) * 2019-10-24 2021-04-29 Amgen Inc. Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer
WO2022132200A1 (en) * 2020-12-15 2022-06-23 Mirati Therapeutics, Inc. Azaquinazoline pan-kras inhibitors
WO2022228568A1 (zh) * 2021-04-30 2022-11-03 劲方医药科技(上海)有限公司 吡啶或嘧啶并环类化合物,其制法与医药上的用途
WO2022248885A2 (en) * 2021-05-28 2022-12-01 Redx Pharma Plc. Compounds
WO2023274324A1 (zh) * 2021-06-30 2023-01-05 上海艾力斯医药科技股份有限公司 一种含氮杂环化合物、其制备方法、中间体及应用

Also Published As

Publication number Publication date
CA3228310A1 (en) 2023-02-16
AU2022325771A1 (en) 2024-02-15
WO2023018812A1 (en) 2023-02-16
MX2024001893A (es) 2024-02-29
TW202330529A (zh) 2023-08-01
EP4384160A1 (en) 2024-06-19
EP4384160A4 (en) 2025-10-29

Similar Documents

Publication Publication Date Title
AU2022325771A1 (en) Heterocyclic compounds and methods of use
US12570672B2 (en) Macrocyclic compounds and methods of use
US20250179077A1 (en) Quinazoline compounds and uses thereof as inhibitors of mutant kras proteins
JP2024532733A (ja) 複素環式化合物及び使用方法
TW202321242A (zh) 雜環化合物及使用方法
US20250059179A1 (en) Heterocyclic Compounds and Methods of Use
US20250163064A1 (en) Quinazoline compounds and uses thereof as inhibitors of mutant kras proteins
JP2024517695A (ja) 複素環式化合物及び使用方法
AU2023477424A1 (en) Indazole containing compounds and methods of use
WO2025194057A1 (en) Macrocyclic compounds as modulators of kras and uses thereof
WO2025230878A1 (en) Macrocyclic compounds as modulators of kras and uses thereof
WO2025230862A1 (en) Macrocyclic amino compounds as modulators of kras and uses therof
CN117881397A (zh) 杂环化合物及使用方法
US20250034167A1 (en) Heterocyclic compounds and methods of use
CN117897159A (zh) 杂环化合物及使用方法
CN117835976A (zh) 杂环化合物及使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250808

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250808

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260421

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260424

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260716